The preservative-free solution is commonly used in the management of Dry Eye Disease (DED) and related chronic conditions. It is applied across domains where additional symptomatic support is needed, generally providing support to help ease symptoms related to physical discomfort, such as soreness, grittiness, and irritation. This application may help reduce the overall burden of persistent symptomatic manifestations. Such agents are utilized for addressing the discomfort associated with dry eye.

Key Symptomatic Indications and Uses

Hyabak 0.15% is commonly used across conditions presenting with recurrent or episodic manifestations of dryness. This includes:

1. Chronic Dryness: Used for managing symptoms linked to long-term dry eye disease.
2. Environmental Strain: Applied when symptoms intensify due to factors like wind, air conditioning, or pollution.
3. Digital Fatigue: Relevant for easing strain symptoms caused by prolonged computer screen use.
4. Contact Lens Discomfort: Used by lens wearers to maintain functional stability and comfort.

“The product is considered relevant in contexts marked by increased discomfort and assists with maintaining functional stability.”

Quick Fact: Relief for Physical Discomfort

The solution provides support that helps ease the overall symptom burden, assisting with maintaining functional stability and comfort during periods of heightened symptoms.

Regulatory References

1. NHS guidance on Sodium Hyaluronate Eye Drops

The official population eligibility for Hyabak 0.15% is determined by regulatory criteria, focusing on ingredient sensitivity and patient age groups. The classification defines who is permitted to use the eye drops, who is restricted, and who is absolutely prohibited.

Eligibility Status Summary

Populations with Restrictions or Contraindications

The regulatory documents establish clear limitations for specific groups:

• Contraindication (Must Not Use): Use of Hyabak 0.15% is absolutely contraindicated in patients who have a known hypersensitivity or allergy to Sodium Hyaluronate or any other ingredient in the formulation.
• Children (Under 18): Use in the pediatric population is not recommended in the absence of sufficient data regarding effects in this age group.
• Pregnant and Breastfeeding Women: Use during pregnancy or lactation is not recommended due to an absence of sufficient data; use is conditional and should only occur if advised by a healthcare professional.
• Organ Impairment: The official labeling does not document any specific restrictions based on conditions such as renal or hepatic impairment.

This regulatory framework ensures that while the product is generally allowed for adults, its use is strictly limited or prohibited where regulatory data is insufficient or a risk of allergy exists.

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Hyabak 0.15% based on its strictly local, non-systemic use. As an ocular protective agent, the active ingredient, Sodium Hyaluronate, is administered directly to the eye and demonstrates negligible absorption into the systemic circulation. This characteristic determines that Hyabak 0.15% does not participate in or cause documented systemic interactions with other medicines or substances.

Consequently, official prescribing information contains no statements regarding complex systemic interactions, such as those related to metabolic pathways (like CYP enzymes), drug transporter systems (e.g., P-gp), or systemic pharmacodynamic effects. Due to this localized action, interactions with food, alcohol, herbal products, or supplements are not anticipated or documented in regulatory labels.

The only interaction officially recognized is a local, physical constraint requiring careful procedural management. This interaction involves the co-administration of other topically administered ocular medicinal products. The regulatory restriction mandates that these other eye treatments be applied with a mandatory separation in time. This is classified as a local interaction requiring procedural management to prevent physical interference or wash-out, thereby ensuring both products can fully exert their intended local effect on the ocular surface. This administration timing constraint constitutes the only significant interaction-related requirement stated in the official regulatory profile.

The mechanism-of-action of Hyabak 0.15% is mediated by its active component, sodium hyaluronate (HA), a high-molecular-weight polysaccharide naturally present in ocular and connective tissues. Upon instillation, HA molecules interact with the corneal and conjunctival epithelial cell layers. Due to its hydrophilic nature, HA retains water molecules and forms a continuous, stable viscoelastic layer on the ocular surface. This biophysical action mechanically enhances the aqueous layer of the tear film, increasing its volume and residence time on the eye. The high viscosity index of the solution facilitates a reduction in the shear forces experienced by the microvilli of the corneal epithelium during blinking. This molecular interaction between the HA matrix and the cellular surface contributes to the physiologic stabilization of the tear film integrity. This mechanism modulates the local biomechanical environment without engaging in specific receptor binding or enzymatic pathway inhibition.

Instruction Map: How to use Hyabak 0.15%

The following guidelines outline the standard administration protocol for Hyabak 0.15% Ophthalmic Solution. The information describes administration parameters and excludes safety, mechanism, and therapeutic claims.

Administration Scope

Instruction Classifications

Resulting Procedural Structure

The administration sequence dictates that the bottle tip must not touch any surface during use to prevent contamination. The product is used as supplied, with no dilution required. Following administration of the single drop into the eyelid pocket, the eye should be closed gently. The preservative-free multi-dose container uses the ABAK system, which ensures the solution remains sterile for the defined duration.

Connection to the overall use protocol: The administration sequence follows an intermittent, symptom-driven use protocol defining the ophthalmic route and the fixed unit dose of one drop per application. This structure permits use throughout the day and sets a 10-minute waiting period between applications of Hyabak and other ocular treatments, defining the administration sequence.

Research Evidence / Overview of Studies for Hyabak 0.15%

Evidence for Use in Chronic Dry Eye Disease and General Ocular Discomfort

The research base for Sodium Hyaluronate 0.15% in this context includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined patient-reported experiences in populations with dry eye disease (DED) and its associated symptoms, such as discomfort and grittiness.

Researchers primarily studied adults and older adults. Outcomes monitored included patient-reported outcomes describing perceived discomfort (e.g., OSDI scores) and objective measures of the tear film (e.g., Tear Film Break-up Time - TBUT), along with ocular surface status assessed via standardized staining. The research base includes evidence categorized as Moderate.

Evidence for Use Following Ocular Surgery

Research explored the use of the solution in patients following common procedures like cataract surgery (phacoemulsification). These studies were conducted during periods where symptoms become more noticeable due to the nature of the recovery process.

The clinical research examined outcomes related to physical discomfort using patient questionnaires, along with measures of the eye's healing process. Some trials reported patterns related to post-operative symptom scores when comparing the solution to other standard care regimens. The follow-up durations for studies in this scenario were generally limited to the short-term, typically assessing outcomes at one, three, and six weeks after the procedure.

What Remains Uncertain in the Research

Evidence highlights what is known—and what is still uncertain—about this product’s profile. A main research limitation is the variability across studies, where findings describing group patterns were sometimes mixed when comparing data on subjective reports against data on objective clinical measures. The follow-up durations were limited in many controlled trials, suggesting that long-term effects are not fully established. Additionally, data for certain groups, like children and adolescents, remain insufficient in the major controlled trials.

Key Studies & References

1. Sodium Hyaluronate 0.2% Eye Drops - Patient Information Leaflet (University Hospitals Sussex NHS Foundation Trust)
2. Prescribing Guidelines for Dry Eye (BSW Together NHS Guidance)

Common questions about Hyabak 0.15% (FAQ)

Q: Is Hyabak 0.15% the same as just saline eye drops?

A: No, according to official information. Hyabak 0.15% contains Sodium Hyaluronate, which is a key component of the product's action. This substance is a viscoelastic agent, meaning it forms a stable layer on the eye that clinical studies support its role in providing greater stability to the tear film compared to simple saline solutions.

Q: Does Hyabak 0.15% help with red eyes?

A: Official product indications state the solution is used to relieve symptoms of ocular irritation and discomfort. If mild redness is associated with these symptoms of dryness, the product's action may help to alleviate these symptoms. However, ocular redness is also cited in safety documents as a possible, temporary side effect after application.

Q: Is Hyabak 0.15% suitable for long-term use?

A: Regulatory guidance for the preservative-free formulation indicates suitability for long-term use, especially for patients who require drops frequently or over extended periods. This formulation choice is often favored to minimize potential irritation associated with chemical additives during chronic application.

Q: How quickly does Hyabak 0.15% start to feel effective?

A: The lubricating and friction-reducing effects of the product are generally expected to begin immediately after instillation. Studies examining the relief of symptoms have measured positive improvement starting within the first few minutes of application.

Q: Are there any known issues with using Hyabak 0.15% and glaucoma drops?

A: Official regulatory texts mandate a procedural restriction regarding use with all other topical eye products, which includes prescription medications like glaucoma drops. The requirement is to wait a minimum of 10 minutes between the administration of Hyabak and the other eye product to prevent physical wash-out.

Q: Can Hyabak 0.15% be used by people with sensitive eyes?

A: The preservative-free formulation, which uses the specialized ABAK system, is designed to minimize the potential for irritation often associated with chemical preservatives in eye drops. This formulation promotes high ocular tolerance, making it a formulation that is generally chosen for people with sensitive eyes.

Q: Is Hyabak 0.15% safe for people with certain eye conditions?

A: Regulatory documentation advises caution. Safety warnings related to use in surgical contexts have noted potential for transient increases in intraocular pressure (IOP) and isolated reports of corneal edema. Information about use for any pre-existing eye condition is best reviewed by a healthcare professional.

Q: What should I do if I accidentally use too much Hyabak 0.15%?

A: Official patient information indicates there is generally no cause for concern if a few extra drops are administered to the eye. The body can naturally handle the small amount of solution, and overdose or damage from excessive topical application is not anticipated.

Q: What is the expected length of time for the soothing effect after application?

A: Studies have examined the duration of the effect on tear film stability and symptomatic relief. Evidence indicates the action is prolonged compared to simple drops and can last for an extended period, with effects measured for up to 6 hours per application.

Q: Is Hyabak 0.15% available over the counter or does it require a prescription?

A: The product is generally classified as an ocular protective agent and is typically available for use without a prescription (Over-The-Counter or General Sale) in many markets.

Q: Is Hyabak 0.15% known to cause light sensitivity?

A: Yes, official safety documentation notes that sensitivity to light (photophobia) has been reported as a side effect. This effect is usually described as transient and temporary.

Q: What is the evidence level for Hyabak 0.15% in treating computer vision syndrome-related dryness?

A: Official product usage rationales explicitly note that the solution is suitable for addressing dryness or eye fatigue caused by various environmental factors. This includes relief from symptoms of discomfort related to intensive computer use.

Q: Can Hyabak 0.15% be used by people who have had LASIK surgery?

A: Yes, preservative-free sodium hyaluronate solutions are frequently recommended for use in the post-operative schedule following procedures like LASIK surgery. They are used to manage symptoms of dryness and provide lubrication, which may be part of a post-operative regimen.

Q: Is the feeling of a 'film' or 'gooey' texture normal after using Hyabak 0.15%?

A: The product's mechanism relies on its viscoelastic properties, meaning it forms a cohesive, moisturizing film on the ocular surface. This film provides sustained lubrication and friction reduction, and this action is what may be perceived as a temporary 'film' sensation.

Q: Does using Hyabak 0.15% frequently reduce the eye's natural tear production?

A: No, regulatory evidence suggests that this type of product acts as a tear film substitute. It is documented to enhance tear film stability and support the eye's natural fluid layer without containing ingredients known to reduce the eye’s own tear production.

Q: What happens if I use Hyabak 0.15% past the official expiration date?

A: Official safety warnings indicate the product should not be used after the stated expiration or discard date. Continued use risks a loss of effectiveness or an increased risk of eye infection due to potential degradation or diminished sterility of the solution.

Q: Can Hyabak 0.15% be used to soothe irritation from dust or environmental factors?

A: Yes, the product is indicated to provide symptomatic relief from dryness and eye fatigue caused by a variety of environmental factors. Official documents mention external causes such as wind, smoke, or pollution.

Q: What are the general expectations for improvement when using Hyabak 0.15%?

A: Based on clinical evidence, users may experience relief, with effects on comfort often noticed immediately upon application. This is associated with a noticeable improvement in comfort and tear film stability that can last for an extended period.

Q: Does Hyabak 0.15% contain any animal-derived ingredients?

A: Official documentation indicates that the active ingredient, Sodium Hyaluronate, is a biomimetic polysaccharide derived through bio-fermentation. This is a manufacturing process that typically does not utilize animal products.

Q: What is the purpose of the 0.15% concentration specifically?

A: The concentration of 0.15% is supported by clinical evidence as being within the necessary range to effectively stabilize the tear film. This concentration is used to provide the intended moisturizing and lubricating effect for symptomatic relief of dry eye conditions.

Q: What is the difference between Hyabak and generic sodium hyaluronate drops?

A: The official documents note a key distinguishing factor is the product's formulation, which uses the specialized ABAK system dispenser. This system ensures the solution remains completely preservative-free throughout its use, promoting high ocular tolerance.

Q: Can Hyabak 0.15% be used to help with excessive tearing?

A: The solution is primarily indicated for dryness and works by restoring tear film stability. If excessive tearing is a reflex symptom of underlying dry eye, improving the tear film may help. It is noted in safety information that 'increased tearing' is also a documented side effect.

Q: What are the safety warnings for using Hyabak 0.15% in cold or hot weather?

A: Official storage guidelines specify a required temperature range. If refrigerated, the solution should be allowed to reach room temperature before use.

Q: What kind of studies have compared Hyabak 0.15% to no treatment?

A: The clinical efficacy of the active ingredient is established through randomized controlled trials. These trials often compare the product against a non-medicated solution, such as saline (a vehicle control), to accurately measure the lubricating and stabilizing effects of the active ingredient.

Q: Can I use Hyabak 0.15% to clean my contact lenses?

A: Official documentation states the solution is intended to lubricate and hydrate contact lenses to improve comfort during insertion and wear. While it is documented to help decrease protein adhesion, it is not formally labelled as a lens cleaning solution.

Q: Can children use Hyabak 0.15%?

A: Official regulatory guidance advises that use in the pediatric population is not recommended due to the absence of sufficient dedicated data regarding effects in this age group. Use is recommended only under the specific advice and supervision of a healthcare professional due to the limited dedicated data.

How to Store and Dispose of Hyabak 0.15%

The storage and disposal of Hyabak 0.15% are governed by specific regulatory requirements to maintain product stability and safety.

Storage Conditions

The product must not be used after the expiry date. Furthermore, regulatory documents specify various post-opening discard periods, such as mathbf6 months, mathbf3 months, or mathbf8 weeks, after the first opening.

Disposal Instructions

Unused or expired Hyabak 0.15% and its packaging must be disposed of in accordance with local medicinal waste regulations. The medicine should not be thrown away with standard household waste or flushed into wastewater.